Few genetic findings carry the emotional weight of an APOE result. APOE is the strongest common genetic risk factor for late-onset Alzheimer's disease, and unlike most polygenic risk findings, the effect size is large enough to matter individually.
It's also, partly for that reason, one of the most ethically debated variants to surface in a consumer genomic-health report. We surface it. We do so with care. Here's the rationale and the evidence.
What APOE does
APOE encodes apolipoprotein E, a lipid-transport protein in the brain and bloodstream. It comes in three main alleles — ε2, ε3, ε4 — defined by two SNP variants (rs429358 and rs7412). You inherit one from each parent, giving six possible genotypes:
- ε2/ε2 (rare, ~0.5% of population)
- ε2/ε3 (~10%)
- ε2/ε4 (~2%)
- ε3/ε3 (most common, ~60%)
- ε3/ε4 (~22%)
- ε4/ε4 (~2%)
ε3 is the reference allele. ε2 is mildly protective. ε4 is the risk allele.
What the evidence shows for Alzheimer's
Late-onset Alzheimer's lifetime-risk numbers from large meta-analyses (Genin et al., 2011; Rasmussen et al., 2018, others):
- No ε4 alleles (ε3/ε3, ε2/ε3, ε2/ε2): ~10-15% lifetime risk by age 85
- One ε4 allele (ε3/ε4): ~20-25% lifetime risk
- Two ε4 alleles (ε4/ε4): ~50-60% lifetime risk
The ε2 allele is independently protective: ε2/ε3 carriers have ~40% reduced risk vs ε3/ε3.
These numbers are for the population overall. Family history, sex, ancestry, and environmental factors modify them substantially.
What APOE does NOT mean
APOE is not deterministic. Even ε4/ε4 homozygotes have a ~40-50% chance of not developing Alzheimer's by age 85. Not every ε4/ε4 carrier develops the disease, and many ε3/ε3 carriers do.
APOE is not the only Alzheimer's risk factor. Family history captures additional rare variants (PSEN1, PSEN2, APP) that cause early-onset autosomal-dominant Alzheimer's. These are far rarer (<1% of all cases) but penetrance is near-100%. APOE doesn't tell you about those.
APOE is one variant among thousands. Newer polygenic risk scores for Alzheimer's are showing meaningful effect sizes that operate independently of APOE. A complete picture combines APOE genotype + polygenic risk + family history + lifestyle.
Modifiable risk factors that matter
For ε4 carriers specifically, growing evidence suggests these interventions reduce risk:
- Cardiovascular health (BP control, lipid management) — APOE risk operates partly through vascular pathways
- Sleep — particularly deep / slow-wave sleep, which clears amyloid via the glymphatic system
- Aerobic exercise — robustly associated with reduced risk in observational and RCT data
- Hearing aids if hearing-impaired — Lancet Commission on Dementia identified hearing loss as the largest modifiable risk factor
- Mediterranean / MIND diet — moderate evidence
- Cognitive engagement — modest but real
The 2024 Lancet Commission on Dementia estimated that ~45% of dementia cases worldwide could potentially be prevented by addressing 14 modifiable risk factors. APOE-positive individuals appear to benefit from intervention at least as much as APOE-negative — possibly more.
Should you want to know your APOE status?
Reasonable people disagree.
Arguments for knowing: Modifiable risk factors are real; behavior change is more likely with personal data; family planning, retirement planning, and care planning may be informed; some people simply want to know.
Arguments against: Anxiety; insurance discrimination concerns (note: in the US, GINA prohibits health insurance and employment discrimination based on genetic information, but does NOT cover life insurance, long-term care insurance, or disability insurance); the result is probabilistic, not diagnostic.
The middle ground: Know it, but contextualize. APOE alone doesn't determine your future; lifestyle response matters. If you're going to find out, also commit to a baseline cognitive assessment + heart/sleep/exercise check-up to establish a starting point.
How Atlagene reports APOE
Atlagene reports APOE genotype as part of the neurological category for Premium users. The report includes:
- Your genotype (ε2/ε3, ε3/ε3, ε3/ε4, etc.)
- Lifetime-risk implication based on meta-analyses
- Modifiable risk factors with evidence strength
- A note that this is probabilistic, not deterministic
- An option to request physician review for ε3/ε4 or ε4/ε4 findings (included in Premium + Physician)
We chose to surface APOE rather than gate it. Per our policy stance, all results are shown to all users with disclaimers — physician review is the paid product for clinically significant findings.
A note on insurance
GINA (Genetic Information Nondiscrimination Act, 2008) prohibits health insurance and employment discrimination based on genetic information in the United States. GINA does NOT cover:
- Life insurance
- Long-term care insurance
- Disability insurance
- Active military
If you're considering testing and life/LTC insurance is a concern, secure those policies before genetic testing. This is independent of which platform you use; insurers can ask whether you've had genetic testing and base decisions on that.
See our GINA notice for details on what is and isn't covered.
What to do with an ε4 finding
- Don't panic. ~25% of the population carries at least one ε4. Most won't develop Alzheimer's.
- Establish a baseline. Cognitive assessment, BP, lipid panel, sleep evaluation if symptoms.
- Address modifiable risk factors — cardiovascular, sleep, exercise, hearing if relevant.
- If family history is also positive, consider physician review or genetic counseling.
- Plan, don't catastrophize. Long-term care planning is reasonable; daily anxiety is not productive.
Read about our methodology or browse the variants we analyze.